Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 5:07 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1897–1920 of 4,736 matching trials from the live ClinicalTrials.gov search.
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
fluticasone and salmeterol
Drug
Lead sponsor
University of Chicago
Other
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Long COVID
Interventions
WATER+CT, Usual Care
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 89 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Completed No phase listed Observational

VCSIP Follow-up Study

NCT03203603
Conditions
Asthma, Pulmonary Function, Wheezing, In Utero Nicotine
Interventions
No active intervention
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
6 Months to 4 Years
Enrollment
242 participants
Timeline
2017 – 2024
U.S. locations
2
States / cities
Indianapolis, Indiana • Portland, Oregon
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
Huntington Memorial Hospital
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Pasadena, California
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chemotherapy-Related Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Hodgkin Lymphoma, Langerhans Cell Histiocytosis, Minimal Residual Disease, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Non-Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Myelodysplastic Syndrome, Small Lymphocytic Lymphoma, Therapy-Related Myelodysplastic Syndrome
Interventions
Anti-Thymocyte Globulin, Busulfan, Clofarabine, Cyclophosphamide, Filgrastim-sndz, Fludarabine, Melphalan, Mycophenolate Mofetil, Rituximab, Tacrolimus, Total-Body Irradiation, Umbilical Cord Blood Transplantation
Biological · Drug · Radiation + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Houston, Texas
Not listed No phase listed Observational

Perioperative Vaping Complications

NCT05912023
Conditions
Vaping, Complication of Anesthesia
Interventions
Not listed
Lead sponsor
Navy Medical Center San Diego
Federal
Eligibility
12 Years to 80 Years
Enrollment
300 participants
Timeline
2023 – 2025
U.S. locations
1
States / cities
San Diego, California
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Pamrevlumab, Placebo
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
40 Years to 85 Years
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
60
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more
Conditions
Obesity, Respiratory Insufficiency
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
40 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
Evanston, Illinois • Chapel Hill, North Carolina • Durham, North Carolina + 1 more
Conditions
Chronic Obstructive Pulmonary Disease, Emphysema, Chronic Bronchitis With Airway Obstruction
Interventions
Quercetin 1000 mg, Quercetin 500 MG, Placebo
Drug
Lead sponsor
Temple University
Other
Eligibility
40 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Moderate to Severe Chronic Obstructive Pulmonary Disease
Interventions
PF-07275315 dose 1, PF-07275315-dose 2, Placebo, PF-07275315-dose 3
Drug
Lead sponsor
Pfizer
Industry
Eligibility
35 Years to 80 Years
Enrollment
1,156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
66
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 50 more
Conditions
COPD, Chronic Bronchitis
Interventions
Losartan 50 mg, Losartan 100 mg
Drug
Lead sponsor
University of Miami
Other
Eligibility
35 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Miami, Florida
Conditions
Covid19
Interventions
Hyperbaric oxygen therapy
Combination Product
Lead sponsor
Peter Lindholm
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
La Jolla, California
Conditions
Fibrosis Lung
Interventions
FAPI tracer, PET/MRI
Drug · Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Asthma
Interventions
QAW039, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
894 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
55
States / cities
Birmingham, Alabama • Gilbert, Arizona • Litchfield Park, Arizona + 49 more
Conditions
Brain Injury Traumatic Severe (Diagnosis), Coma, Consciousness, Level Altered, Anoxic Brain Injury
Interventions
Methylphenidate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Idiopathic Pulmonary Fibrosis, Emphysema or COPD
Interventions
CD3/CD19 negative hematopoietic stem cells, Rituximab, Alemtuzumab, Fludarabine, Thiotepa, G-CSF, Hydroxyurea
Biological · Drug
Lead sponsor
Paul Szabolcs
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Conditions
Pulmonary Arterial Hypertension
Interventions
Sodium Nitrite Inhalation Solution, Placebo and AIR001 Inhalation Solution (Expansion arm)
Drug
Lead sponsor
Aires Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Non Small Cell Lung Cancer, Lung Cancer Stage 1
Interventions
Liposomal Bupivacaine, Bupivacaine-Epinephrine
Drug
Lead sponsor
Southern Illinois University
Other
Eligibility
18 Years to 80 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Springfield, Illinois
Conditions
AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hepatocellular Carcinoma, HIV Infection, Kaposi Sarcoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma, Recurrent Malignant Neoplasm, Refractory Classic Hodgkin Lymphoma, Refractory Malignant Neoplasm, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Unresectable Melanoma
Interventions
Antiretroviral Therapy, Biopsy, Biospecimen Collection, Computed Tomography, Pembrolizumab, Positron Emission Tomography
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
12
States / cities
Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 6 more
Conditions
COPD
Interventions
QBM076, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
35 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Cystic Fibrosis in Children, Cystic Fibrosis, Chronic Rhinosinusitis (Diagnosis), Olfactory Disorder, Olfactory Impairment
Interventions
Ivacaftor or elexacaftor/tezacaftor/ivacaftor
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
2 Years to 8 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
6
States / cities
Aurora, Colorado • Iowa City, Iowa • Kansas City, Kansas + 3 more
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hematopoietic and Lymphoid Cell Neoplasm, Hormone Receptor Positive Breast Adenocarcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Triple-Negative Breast Carcinoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Bintrafusp Alfa, Pimasertib, Quality-of-Life Assessment
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Conditions
Non-Small Cell Lung Cancer
Interventions
MEDI4736
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
28
States / cities
Goodyear, Arizona • Santa Rosa, California • New Haven, Connecticut + 22 more